Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 index in the ROCKET AF

Circulation

Volumn 127, Issue 2, 2013, Pages 224-232

  Piccini, Jonathan P ^a   Stevens, Susanna R ^a   Chang, Yuchiao ^c   Singer, Daniel E ^c   Lokhnygina, Yuliya ^a   Go, Alan S ^d   Patel, Manesh R ^a   Mahaffey, Kenneth W ^a   Halperin, Jonathan L ^e   Breithardt, Günter ^f   Hankey, Graeme J ^g   Hacke, Werner ^h   Becker, Richard C ^a   Nessel, Christopher C ⁱ   Fox, Keith A A ^j   Califf, Robert M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DIVISION OF RESEARCH   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g ROYAL PERTH HOSPITAL   (Australia)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^j ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

more..

Author keywords

atrial fibrillation; chronic kidney diseases; risk stratification; stroke

Indexed keywords

CREATININE; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLASSIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; VALIDATION STUDY;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMBOLISM; FACTOR XA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MORPHOLINES; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STROKE; THIOPHENES; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84872345697     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.107128     Document Type: Article

References (22)

1. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Heuzey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fbrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144-1150.
2. Estes NA 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJ, Waldo AL, Wyse DG; American College of Cardiology/American Heart Association Task Force on Performance Measures; Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation); Heart Rhythm Society. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonval-vular atrial fbrillation or atrial futter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation. 2008;117:1101-1120.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classifcation schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refning clinical risk stratifcation for predicting stroke and thromboembolism in atrial fbrilla-tion using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.
5. Rocket AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fbrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.e341.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
7. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fbrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.
8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fbrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
9. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jen-svold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fbrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classifcation, and stratifcation. Am J Kidney Dis. 2002;39:S1-S266.
11. Harrell FEJ. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression and Survival Analysis. New York, NY: Springer-Verlag; 2001.
12. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifcation and beyond. Stat Med. 2008;27:157-172.
13. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, Warnock DG, Muntner P. Association of chronic kidney disease with atrial fbrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Elec-trophysiol. 2011;4:26-32.
14. Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, Ta-guchi Y, Dougu N, Nozawa T, Tanaka K, Inoue H. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fbrillation. Am J Cardiol. 2011;107:912-916.
15. Tokuda M, Yamane T, Matsuo S, Ito K, Narui R, Hioki M, Tanigawa S, Nakane T, Yamashita S, Inada K, Shibayama K, Miyanaga S, Yoshida H, Miyazaki H, Date T, Yokoo T, Yoshimura M. Relationship between renal function and the risk of recurrent atrial fbrillation following catheter ablation. Heart. 2011;97:137-142.
16. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE; ATRIA Study Group. Comparison of risk stratifcation schemes to predict thromboembolism in people with nonvalvular atrial fbrillation. J Am Coll Cardiol. 2008;51:810-815.
17. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
18. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mus-solino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
19. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratifcation schemes in an anticoagulated atrial fbrillation cohort. Stroke. 2010;41:2731-2738.
20. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
21. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
22. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL; American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873-e923.